J. Joseph Melenhorst

Cleveland Clinic — United States

Medicine · Health Sciences

59h-index29.7kcitations292works9.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(219), Acute Lymphoblastic Leukemia research(55), Immune Cell Function and Interaction(51), Chronic Lymphocytic Leukemia Research(38), Viral Infectious Diseases and Gene Expression in Insects(32)

Publications292 total

Mastering Organoid Growth: A Complete Guide to Overcoming Methodological Challenges
MedComm·2026Open Access
Correction: NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model
Scientific Reports·2025Open Access
Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma
Blood·2025Open Access
Patient-informed CRISPR screening reveals gene targets to improve CAR T-cell efficacy
Blood·2025Open Access
Novel approaches to identify cellular vulnerabilities in TET2-dependent MDS
Blood·2025Open Access
NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model
Scientific Reports·2025Open Access
Fine tuning towards the next generation of engineered T cells
Nature Biomedical Engineering·2025· 3 citedOpen Access
MCL1 may not mediate chemoresistance
2025Open Access
A phase Ib study to assess the safety and efficacy of autologous tumor infiltrating lymphocytes (lifileucel) with adjuvant pembrolizumab (PEMBRO) for treatment of immunotherapy naïve patients with high-risk clinical stage IIIb-d resectable melanoma (MEL).
Journal of Clinical Oncology·2025· 1 cited
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma
Journal of Clinical Oncology·2025· 1 cited
DEVELOPMENT AND CLINICAL VALIDATION OF A LESS THAN 1 DAY CAR-T MANUFACTURING PROCESS
Cytotherapy·2025
Abstract 3210: Neoadjuvant-adjuvant pembrolizumab (PEMBRO) in advanced basal cell carcinoma (BCC) induces memory-like T cell expansion with therapeutic promise
Cancer Research·2025
Abstract 6797: Mechanisms of nuclear MCL1 mediated chemoresistance
Cancer Research·2025
Abstract 3807: Validation of a functional genomics screen based on lentiviral integration site analysis reveals single-gene disruptions enhancing CAR19 T-cell effectiveness in preclinical models
Cancer Research·2025
Abstract B091: A Phase 1b study of neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma reveals robust T cell expansion, driving a memory-like subtype with promising therapeutic potential
Cancer Immunology Research·2025
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
Cancers·2025· 3 citedOpen Access
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Nature Medicine·2025· 58 cited
Navigating CAR-T cell therapy long-term complications
Nature Cancer·2024· 4 cited
TET2 regulates early and late transitions in exhausted CD8 <sup>+</sup> T cell differentiation and limits CAR T cell function
Science Advances·2024· 18 citedOpen Access
Low Regimen Therapeutic Strategies to Mitigate TET2 Mutant Clonal Hematopoiesis
Blood·2024
page 1 of 15Next →

Frequent Co-authors

Carl H. June(44), Simon F. Lacey(43), Bruce L. Levine(30), David L. Porter(17), Noelle V. Frey(16), Stephan A. Grupp(16), Joseph A. Fraietta(13), Shannon L. Maude(12), Wei‐Ting Hwang(12), Irina Kulikovskaya(11), Megan M. Davis(11), Saar Gill(11), Regina M. Young(10), David T. Teachey(8), Stephen J. Schuster(8), Michael C. Milone(8), Farzana Nazimuddin(8), Pamela A. Shaw(7), David M. Barrett(7), Vanessa Gonzalez(7)